Abstract
No empirical studies have defined the posttransplant survival that would justify expansion of the Milan criteria for liver transplantation of hepatocellular carcinoma. We created a Markov model comparing the survival benefit of transplantation for a patient with >Milan HCC, versus the harm caused to other patients on the waiting list. In the base-case analysis, the strategy of transplanting the patient with >Milan HCC resulted in a 44% increased risk of death and a utility loss of 3 quality-adjusted years of life across the pre- and posttransplant periods for a nationally representative cohort of patients on the waiting list. This harm outweighed the benefit of transplantation for a patient with >Milan HCC having a 5-year posttransplant survival of less than 61%. This survival threshold was most sensitive to geographic variations in organ shortage, with the threshold varying from 25% (Region 3) to >72% (Regions 1, 5, 7 and 9). In conclusion, expansion of the Milan criteria will require demonstrating high survival rates for the newly eligible patients - approximately 61% at 5 years after transplantation. In regions with less severe organ shortage, a more aggressive approach to transplanting these patients may be justified.
Original language | English (US) |
---|---|
Pages (from-to) | 839-846 |
Number of pages | 8 |
Journal | American Journal of Transplantation |
Volume | 8 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2008 |
Keywords
- Ethics
- Hepatocellular carcinoma
- Liver transplantation
- Public policy
ASJC Scopus subject areas
- Immunology and Allergy
- Transplantation
- Pharmacology (medical)